Robert Califf, the newly appointed Commissioner of Food and Drugs for the FDA has a long history in healthcare innovation. What his appointment means for patients with health conditions is unknown. Experts say that this may be one of few things that will actually move blockchain into mainstream adoption by non-technical consumers
Robert Califf, who is the current Commissioner of Food and Drugs for the United States Food and Drug Administration (FDA), has announced his resignation. In a statement to the press, he acknowledged that he had failed to sufficiently address tobacco’s role in causing death and disease.
On December 14, Robert Califf, a candidate for FDA Commissioner, will be sworn in.
Michael Brochstein/Zuma Press/Zuma Press/Zuma Press/Zuma Press/Zuma Press
President Biden hasn’t always gone against the grain when it comes to regulatory nominations, but he did so when he named eminent physician Robert Califf to lead the Food and Drug Administration. Nonetheless, the Administration is now putting its candidate on the line.
A Senate committee voted 13-8 in favor of Dr. Califf earlier this month. However, five Democratic Senators, including West Virginia’s Joe Manchin, have expressed opposition to his confirmation, citing his cooperation with pharmaceutical corporations as one of the reasons. As a result, he will require Republican votes to be approved. Pro-life organizations are also rallying against him.
Dr. Califf is not deserving of such treatment. He was confirmed as FDA Commissioner by the Senate 89-4 in 2016, and he oversaw the agency for ten months without substantial controversy. The epidemic has shown the need of having competent FDA leadership, particularly in this age of biotech innovation and medicinal discoveries.
He was a founding member of the Duke Clinical Research Institute in 1996, which supports drug companies with clinical studies. He’s also worked as a health-policy advisor for Verify, Alphabet’s life-sciences research unit, and has done consultancy work for pharma companies. Progressives argue that this implies he is unable to assess medications objectively. As commissioner, though, he exhibited no partiality.
In addition, the FDA need someone who will challenge the agency’s bureaucratic control culture. In the 1980s, the FDA’s caution stymied the development of potential new medicines, including HIV medications. Dr. Califf said in May 2014 that government regulation may act as a “barrier” to innovation.
The CDC was rightfully chastised for approving Covid-19 private lab testing too late in the epidemic. The FDA, on the other hand, moved fast to reduce bureaucracy and collaborate closely with pharmaceutical firms on vaccine and therapeutic studies. This resulted in emergency usage authorisation being granted in record speed.
Dr. Califf described how patient electronic medical information may be used to answer concerns about medications during his December confirmation hearing, but the FDA has been hesitant to do so. Artificial intelligence and cloud computing can assist in the collection of real-time data in order to discover medications that are more likely to work or produce negative effects in certain patient groups.
The progressive public-health community, on the other hand, is opposed to the FDA becoming more flexible, efficient, and responsive. They claim the FDA is granting too many pricey treatments via fast approval, such as Sarepta Therapeutics’ Duchenne muscular dystrophy therapy in 2016 and Biogen’s Aduhelm Alzheimer’s treatment last year.
The claim is that drug companies didn’t follow a double-blind, randomized controlled study to the letter, and FDA officials paid too much heed to patient request for treatments. Both permits were signed off on by Acting Commissioner Janet Woodcock, who seems to have dropped out of the hunt for the Biden candidacy.
Mr. Manchin holds pharma firms responsible for opioid fatalities and holds Dr. Califf responsible as well. Lax prescription procedures are one of the numerous reasons of the opioid crisis. Last year, though, heroin and fentanyl killed five times as many people as prescribed opioids.
Dr. Califf’s pro-life critics are similarly without merit. The FDA has relaxed its standards to enable women to get the abortion drug mifepristone directly from pharmacies or healthcare professionals, codifying a temporary modification made last spring. Despite the fact that Dr. Califf was not engaged in the decision, he said during his December hearing that he trusted “FDA employees to make sound choices” based on the newest evidence.
The FDA is not a body that regulates abortion. The decision was reached based on the danger to the patient, and women must get a prescription. They are not at any increased risk of developing a medical condition if they obtain the medicine via mail rather than picking it up in person. The FDA could not find a compelling medical rationale to limit how the medicine is administered.
Pro-life organizations are concerned that the FDA’s decision would make abortions more easy and, as a result, more widespread. However, the FDA has no authority over this, and states may impose harsher rules than the FDA. Telemedicine visits for abortion drugs are prohibited in several states. Novel gene treatments that might fix birth abnormalities and decrease abortions could be ushered in by an FDA head who favors innovation.
As interim commissioner, Dr. Woodcock has displayed tremendous leadership throughout the epidemic, but the agency needs a Senate-confirmed head. Dr. Califf is well-qualified and deserves stronger political backing from the White House.
Journal Editorial: How will the Supreme Court’s composition alter as a result of this shift? Ilya Shapiro of the Cato Institute is interviewed by Paul Gigot. Images courtesy of Bloomberg News and Getty Images. Mark Kelly’s composite
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
It first appeared in print on January 31, 2022.
Robert Califf is a highly qualified candidate for the position of FDA Commissioner. He has an extensive background in both public health and pharmaceuticals. Reference: robert califf resume.
- dr. robert califf
- robert califf alphabet
- robert califf verily
- robert califf net worth
- robert califf linkedin